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SUMMARY
This study characterized cancer stem cells (CSCs) in hepatocellular carcinoma (HCC) cell lines, tumor spec-
imens, and blood samples. The CD90+ cells, but not the CD90 cells, from HCC cell lines displayed tumori-
genic capacity. All the tumor specimens and 91.6% of blood samples from liver cancer patients bore the
CD45CD90+ population, which could generate tumor nodules in immunodeficient mice. The CD90+CD44+
cells demonstrated a more aggressive phenotype than the CD90+CD44 counterpart and formed metastatic
lesions in the lung of immunodeficient mice. CD44 blockade prevented the formation of local and metastatic
tumor nodules by the CD90+ cells. Differential gene expression profiles were identified in the CD45CD90+
and CD45CD90 cells isolated from tissue and blood samples from liver cancer patients and controls.INTRODUCTION
Cancer stem cells (CSCs) are the source of many solid tumor
types (Al-Hajj et al., 2003; Singh et al., 2004; Collins et al.,
2005; O’Brien et al., 2007; Ricci-Vitiani et al., 2007; Li et al.,
2007), including hepatocellular carcinoma (HCC). HCC is the fifth
most common cancer in the world and comprises more than
90% of human liver cancers. The incidence of HCC is increasing
due to increased rates of hepatitis B and C viral infection (Llovet
et al., 2003; McMahon, 2005; El-Serag, 2004). Hepatic resection
and liver transplantation are the two main treatment modalities
for HCC, and the 5 year survival rate correlates with tumor stag-
ing at the time of diagnosis (Mazzaferro et al., 1996; Llovet et al.,
1999; Arii et al., 2000). The majority of HCC patients present with
an advanced stage of cancer for which chemotherapy and radio-
therapy have limited efficacy (Groupe d’Etude et de Traitement
du Carcinome He´patocellulaire, 1995; Lo et al., 2002). Hence,
understanding the mechanism underlying hepatocarcinogenesis
is essential for the management of liver malignancy.
CSCs have been characterized in solid tumors using a variety of
stem cell markers, including CD133 (Tang et al., 2007). AlthoughCD133 can identify CSCs in cell line-induced HCC (Suetsugu
et al., 2006; Yin et al., 2007; Ma et al., 2007), the CD133+ cells
isolated from human tumor specimens are not well characterized.
Furthermore, the CD133cells also have the capacity to generate
tumor nodules in immunodeficient mice, although at a higher cell
number (Ma et al., 2007). Previously, we showed that CD133 is a
marker of circulating endothelial progenitor cells (EPCs) in HCC
patients (Ho et al., 2006). Together, the above evidence suggests
that CD133 is not sufficiently sensitive or specific to be a marker
of CSCs in liver malignancy.
CD90 (Thy-1) is a 25-37 kDa glycosylphosphatidylinosi-
tol (GPI)-anchored glycoprotein expressed mainly in leukocytes
and is involved in cell-cell and cell-matrix interactions (Rege
and Hagood, 2006). CD90 is also expressed by bone mar-
row-derived mesenchymal stem cells (Dennis et al., 2007)
and hepatic stem/progenitor cells (HSPCs) (La´zaro et al.,
2003; Herrera et al., 2006; Dan et al., 2006). In addition, CD90
expression was identified in murine breast CSCs (Cho et al.,
2007) and primarily cultured CD133+ glioblastoma CSCs (Liu
et al., 2006). Based on the above findings, CD90 was used in
the present study to identify potential hepatic CSCs fromSIGNIFICANCE
This study reveals that CD90 is a potential marker of liver CSCs, and the concomitantly expressed CD44 modulates the
biological activity of the CD90+ CSCs. The presence of local and circulating CSCs implies the aggressive phenotype of liver
malignancy, in which the CD90+CD44+ cells contribute prominently to its aggressiveness andmetastasis. The prevention of
local and systemic tumor formation by CD44 blockade highlights the potential of CD44 as a therapeutic target for CD90+
CSCs. The differential gene expression profiles of CSCs and normal stem cells suggest the importance of these genes in
hepatocarcinogenesis. The identification of local and circulating CSCs provides a cellular basis of liver cancer development,
recurrence, and metastasis and will favor the design of future therapeutic strategies.
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Cancer Stem Cells in Liver MalignancyTable 1. Comparison of Tumorigenic Capacity of the CD90+ Cells from Different HCC Cell Lines
Cell Lines
% of CD90+ Cells
(in Total Cells)
Tumorigenicity
(Cell No.)
Tumorigenicity
(Time) Metastasis
No. of Injected
CD90+ Cells
No. of Mice with Tumor Formation/
Total No. of Mice With Cell Injection
2 Months 3 Months 4 Months
MIHA 0 ND ND
HepG2 0.04 ± 0.01 1 3 107 3 months no 5 3 102 0/3 0/3 0/3
1 3 103 0/3 0/3 1/3
5 3 103 0/3 1/3 0/2
1 3 104 1/3 1/2 1/1
Hep3B 0.45 ± 0.06 1 3 106 2 months no 5 3 102 0/3 0/3 0/3
1 3 103 0/3 1/3 1/2
5 3 103 1/3 1/2 1/1
1 3 104 2/3 1/1
PLC 0.48 ± 0.06 1 3 106 1 month no 5 3 102 0/5 0/5 0/5
1 3 103 1/5 2/4 1/2
5 3 103 4/5 1/1
1 3 104 4/5
Huh7 0.61 ± 0.18 1 3 106 1 month no 5 3 102 0/3 0/3 0/3
1 3 103 1/3 2/2
5 3 103 2/3 1/1
1 3 104 3/3
MHCC97L 2.15 ± 0.14 2 3 105 3 weeks yes 5 3 102 0/6 1/6 1/5
1 3 103 3/5 2/2
5 3 103 5/5
1 3 104 5/5
MHCC97H 2.34 ± 0.3 1 3 105 2 weeks yes 5 3 102 0/3 1/3 1/2
1 3 103 2/3 1/1
5 3 103 3/3
1 3 104 3/3
MIHA is an immortalized nontumorigenic normal human hepatocyte cell line. ND, not determined. The number of the CD90+ cells was expressed as
mean percentage ± SD (representative of three independent experiments). Tumorigenicity by cell number was defined as the lowest number of total
tumor cells that were capable of inducing tumor formation at 2 months after cell injection, whereas tumorigenicity by time was defined as the shortest
time interval that was required for 13 106 total tumor cells to develop tumors. The sorted CD90+ and CD90 cells from different cell lines were injected
subcutaneously into two different sites of a same nude mouse. Animals were sacrificed when tumor nodules were identified in nude mice, otherwise the
mice were monitored continuously until the second or third time point.HCC cell lines, tumor specimens, and blood samples of liver
cancer patients.
RESULTS
Tumorigenic Capacity of CD90+ Cells Isolated
from HCC Cell Lines
Six human HCC cell lines, specifically HepG2, Hep3B, PLC,
Huh7, MHCC97L, and MHCC97H, and one immortalized nontu-
morigenic normal human hepatocyte cell line, MIHA (Pang et al.,
2006), were used to screen for the expression of stem cell
markers by flow cytometry. The tumorigenic potential of the
6 HCC cell lines ranges from low in HepG2 to high in MHCC97H.
In the present study, tumorigenicity is defined as the capacity of
a certain cell number, following serial dilution, to form tumor
nodules in immunodeficient mice within a certain time interval
(Table 1). Three time points were used for the assessment of
tumorigenicity of cell lines and the cells isolated from human
tumor specimens and blood samples. Differentially expressed
154 Cancer Cell 13, 153–166, February 2008 ª2008 Elsevier Inc.stem cell markers were detected in the HCC cell lines, among
which only the expression of CD90 correlated positively with tu-
morigenicity and metastatic properties of cell lines (see Table S1
available with this article online).
The CD90+ cells were isolated from HCC cell lines using mag-
netic microbeads and injected subcutaneously into BALB/c nude
mice using the CD90 cells as a control. Tumor nodules from the
CD90+ cells isolated from both MHCC97L and MHCC97H cell
lines appeared after 3 months from 500 inoculated cells. When
the cell number was increased to 1,000, the CD90+ cells from
4 out of 6 HCC cell lines (PLC, Huh7, MHCC97L, and MHCC97H)
generated tumor nodules in nude mice at 2 months. In cell line
with low tumorigenic capacity, HepG2, a higher number of
CD90+ cells (5,000 cells at 3 months) or a longer observation
time (4 months with 1,000 cells) was needed for tumor develop-
ment (Table 1). In contrast, the CD90 cells from all cell lines
tested did not induce tumor formation in nude mice, even 4
months after injecting 13 104 cells. MHCC97L cell line was cho-
sen to illustrate histological characteristics of tumor xenografts
Cancer Cell
Cancer Stem Cells in Liver MalignancyFigure 1. Tumorigenic Capacity of the
CD90+ or CD90+CD44+ Cells fromMHCC97L
Cell Line
(A) The CD90+ and CD90 cells were isolated from
MHCC97L cell line with a purity ranging from
80.1% to 83.2%, and each cell type was injected
subcutaneously into two different sites of a same
BALB/c nude mouse. After 2 months, the CD90+
cells (cell number = 1 3 104), but not the CD90
cells, formed tumor nodules. Arrows indicate the
site of CD90 or CD90+ cell injection. Similar histo-
logical features were detected by hematoxylin-
eosin (H&E) staining in tumor xenografts generated
by total tumor cells (1 3 106) and the isolated
CD90+ cells (1 3 104). Immunohistochemical
staining (IHC) identifies scattered and clustered
distribution of the CD90+ cells in tumor xenograft.
An arrow points to a cluster of CD90+ cells.
(Ba) Flow cytometry was used to conduct multi-
marker analyses. No CD90+CD44+ cells were
detected in MIHA cell line. In contrast, the
CD90+CD44+ cells were detected in all HCC cell
lines tested (HepG2, 0.02%; Hep3B, 0.31%;
PLC, 0.35%; Huh7, 0.64%; MHCC97L, 2.26%;
MHCC97H, 2.53%).
(Bb) The photo shows a tumor nodule at the site
of injected CD90+CD44+ cells, but not at the site
of injected CD90+CD44 cells. The histological
features of tumor xenograft induced by the
CD90+CD44+ cells are comparable to that induced
by the CD90+ cells. Immunofluorescent staining
(IF) reveals the presence of CD90 and CD44 dou-
ble-positive cells in the generated tumor xeno-
graft. Red, green, and yellow arrows point to the
CD90+, CD44+, and CD90+CD44+ cells, respec-
tively.induced by total tumor cells (13106) and the isolated CD90+ cells
(1 3 104). Hematoxylin-eosin (H&E) staining identified similar
histological features in tumor xenografts generated by the above
two types of cells. Immunohistochemical staining (IHC) analysis
showed scattered and clustered distribution of the CD90+ cells
with both membrane and cytoplasm localization of CD90 expres-
sion (Figure 1A).
Serial transplantation was performed by subcutaneous injec-
tion of the CD90+ cells isolated from tumor xenografts into a sec-
ond and subsequently third batch of nude mice. Tumor nodules
comparable to those isolated from HCC cell lines appeared after
2 months from the CD90+ cells isolated from tumor xenografts
(Table S2A). Flow cytometry showed a similar level of the
CD90+ cells in the first and second generation of tumor xeno-
grafts and HCC cell lines, suggesting a re-establishment of cellu-
lar hierarchy in tumors (Table S2B).
Further multimarker analyses revealed that the majority of
CD90+ cells in HCC cell lines also expressed CD44 (Figure 1Ba),
a marker for HSPCs and an adhesion molecule that modulates tu-
mor cell invasion and migration (Lara-Pezzi et al., 2001). To further
characterize the CD90+ subpopulations, two cell lines, MHCC97L
and PLC (due to their differential distribution of the CD44+ cells),
were used to sort the CD90+CD44+ and CD90+CD44 cells,
which were injected subcutaneously into nude mice to assess
tumorigenicity. Injection of the CD90+CD44 cells at the number
of 2,500 did not result in tumor formation after 4 months. When the
injected cell number of the CD90+CD44 cells was increased to10,000, one mouse developed a tumor after 4 months. On the
contrary, one mouse with 500 CD90+CD44+ cells developed a
tumor nodule at 3 months, and 80% and 100% tumor develop-
ment was observed with 2,500 and 10,000 CD90+CD44+ cells,
respectively, at 2 months after cell injection (Table 2). The histol-
ogy of tumor xenografts induced by the CD90+CD44+ and CD90+
cells was similar. Immunofluorescent staining (IF) identified
CD90+CD44+ cells in tumor specimens (Figure 1Bb).
Inhibition of CD44 Activity Induced CD90+ Cell
Apoptosis In Vitro and Suppressed CD90+ Cell-Induced
Local and Systemic Tumor Engraftments In Vivo
The role of CD44 expression in tumor cells was investigated by
exposing the CD90+ and CD90 cells from the MHCC97L and
PLC cell lines with antihuman CD44 antibody at a range of con-
centrations for 24 hr. Inhibition of CD44 activity by administration
of anti-CD44 antibody induced apoptosis of the CD90+ and
CD90 cells isolated from MHCC97L cell line in a dose-depen-
dent manner. By comparison, blockade of CD44 activity in
PLC cell line only induced the CD90+ cells to undergo apoptosis
and had a mild effect on the CD90 cells (Figure 2A).
The effect of CD44 blockade on tumor formation was further
investigated in vivo. The CD90+ cells from MHCC97L cell line
were injected subcutaneously or directly into the liver of nude
mice to generate local and metastatic tumor models, respec-
tively. Different doses (5 mg/kg or 10 mg/kg, intravenous injec-
tion twice per week) of anti-CD44 antibody were administered
Cancer Cell 13, 153–166, February 2008 ª2008 Elsevier Inc. 155
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Cancer Stem Cells in Liver MalignancyTable 2. Tumorigenic Capacity of the CD90+ and CD90+CD44+ Cells from MHCC97L and PLC Cell Lines
Cell Lines Phenotypes No. of Injected Cells
No. of Mice with Tumor Formation/Total No. of Mice
with Cell Injection (Range of Tumor Size [mm])
2 Months 3 Months 4 Months
MHCC97L CD90+ 5 3 102 0/6 1/6 (3) 1/5 (2.5)
2.5 3 103 3/5 (3–6) 2/2 (2.5–3)
1 3 104 5/5 (3–8)
CD90+CD44+ 5 3 102 0/6 1/6 (4) 1/5 (3.5)
2.5 3 103 4/5 (3–5) 1/1 (2.5)
1 3 104 5/5 (2–5)
CD90+CD44 5 3 102 0/5 0/5 0/5
2.5 3 103 0/5 0/5 0/5
1 3 104 0/5 0/5 1/5 (2)
total tumor cells 1 3 106 5/5 (3–7)
PLC CD90+ 5 3 102 0/5 0/5 0/5
2.5 3 103 2/5 (2–5) 2/3 (2.5–3) 0/1
1 3 104 4/5 (2–6) 1/1 (2)
CD90+CD44+ 5 3 102 0/5 0/5 0/5
2.5 3 103 3/5 (3–4) 1/2 (3) 0/1
1 3 104 5/5 (2.5–5)
CD90+CD44 5 3 102 0/5 0/5 0/5
2.5 3 103 0/5 0/5 0/5
1 3 104 0/5 0/5 1/5 (2)
total tumor cells 1 3 106 4/5 (3–7) 1/1 (2)
The sorted CD90+ and CD90 cells, or CD90+CD44+ and CD90+CD44 cells from different cell lines were injected subcutaneously into two different
sites of a same mouse. Animals were sacrificed when tumor nodules were identified in nude mice, otherwise the mice were monitored continuously
until the second or third time point.into nude mice at the time of cell inoculation. In the absence of
anti-CD44 antibody administration, the CD90+ cells resulted in
tumor formation subcutaneously in more than 80% of nude
mice. Treatment with 5 mg/kg anti-CD44 antibody decreased
the number of tumor-bearing mice, and 10 mg/kg further
inhibited tumor formation (Figure 2B). Likewise, administration
of anti-CD44 antibody also inhibited the engraftment of the
CD90+ cells (cell number = 13 104) isolated from other cell lines
(Hep3B, PLC, and Huh7) (data not shown). In the tumor metasta-
sis model, the CD90 cells from MHCC97L cell line did not
generate liver and lung lesions. By comparison, 100% of mice
developed liver lesion and lung metastasis 4 months after intra-
hepatic injection of 10,000 CD90+ cells. In similar experiments,
the isolated CD90+CD44+ cells induced comparable tumors in
the liver and lung to the CD90+ cells, whereas the CD90+CD44
cells resulted in tumor formation in only 1 out of 6 mice at
4 months. Administration of anti-CD44 antibody prevented the
formation of tumor nodules in the liver and lung induced by the
CD90+ cells (Figure 2Ca). A comparison of cell phenotypes in
the primary and metastatic lesions using antibodies specifically
targeting human CD44 and CD90 showed that, although the
CD44 phenotype contributed to the majority of tumor cells in
both types of lesions, which is consistent with the expression
of CD44 in MHCC97L cell line, the metastatic tumors had a signif-
icantly higher proportion of CD90+ and CD90+CD44+ cells than
primary tumors (Figure 2Cb). The metastatic and primary tumors
displayed similar histological features, and IHC confirmed an
156 Cancer Cell 13, 153–166, February 2008 ª2008 Elsevier Inc.enrichment of the CD90+ cells in metastatic nodules in the lung
(Figure 2Cc).
Validation of Tumorigenic Properties of the
CD45CD90+ Cells Isolated from Human
Tumor Specimens and Blood Samples
Based on the findings in HCC cell lines, CD90 was used as a
marker to characterize CSCs in human tumor specimens, includ-
ing 2 dysplastic nodules, 25 HCCs, and 3 intrahepatic cholangio-
carcinomas (Cholangio Ca). The clinical data of liver cancer
patients and controls is summarized in Table S3A. Since CD90
is also expressed by some lymphocytes, a combination of
CD45CD90+ was used to define nonlymphatic CD90+ cells in
tumor tissues. Flow cytometry revealed the presence of a small
number (0%–0.03%) of CD45CD90+ cells in normal, cirrhotic,
and parallel nontumorous liver specimens. By comparison, the
CD45CD90+ cells (0.03%–6.2%) were detected in all the tumor
specimens (Table S3b). Our findings are consistent with the
reports of the CD90+ cells at 0.01% in the normal adult liver
(Nava et al., 2005), and higher levels in neoplastic tissues (Cea-
falan et al., 2005). Multimarker analyses demonstrated that a pro-
portion of CD45CD90+ cells in tumor tissue concomitantly
expressed stem cell markers, including CD44 (Figures 3Aa and
3Ab), CD133 (Table S3B), ESA, CXCR4, CD24, and KDR (Table
S4). Interestingly, small numbers of CD45CD90+ cells were
also detected in one of the two dysplastic nodules, a precancer-
ous stage of HCC (Table S3b).
Cancer Cell
Cancer Stem Cells in Liver MalignancyFigure 2. The Effect of CD44 Expression on the Biological Activity of the CD90+ and CD90 Cells In Vitro and In Vivo
(A) The CD90+ and CD90 cells were isolated from MHCC97L and PLC cell lines and seeded into 6-well culture plates. Different doses of anti-CD44 antibody
(0, 1.5, 3, 6, 12, or 24 mg/ml) were added into the plate and incubated for 24 hr. The cells were labeled with Annexin V and PI and detected by a FACSCalibur.
The dot plots represent typical features of Annexin V and PI staining. Treatment with anti-CD44 antibody induced a significant increase in cell apoptosis in both
CD90+ and CD90 cells isolated from MHCC97L cell line, but only the CD90+ isolated from PLC cell line. *p < 0.05, compared with the CD90+ cells without treat-
ment (0 mg/ml anti-CD44 antibody); #p < 0.05, compared with the CD90 cells without treatment. The number of apoptotic cells is expressed as mean percentage
± SD from three independent experiments.
(B) Anti-CD44 antibody (5 mg/kg or 10 mg/kg twice per week, n = 6 in each group) was injected intravenously into BALB/c nude mice at the time of subcutaneous
injection of the CD90+ cells isolated from MHCC97L cell line. After 2 months, a decrease in the number of tumor-bearing mice was observed with anti-CD44
treatment. The bar chart shows tumor formation rates of different groups (n = 6 in each group). NT, no treatment. *p < 0.05, compared with NT.
(C) Phenotypically different cells isolated from MHCC97L cell line were injected orthotopically into the left lobe of the liver of BALB/c nude mice, respectively. Anti-
CD44 antibody (10 mg/kg twice per week) was administered intravenously at the time of cell inoculation. After 4 months, animals were sacrificed to assess the
formation of liver and metastatic lung lesions.
(Ca) The CD90 cells did not induce lung metastasis, whereas the CD90+CD44+ cells induced tumor nodules in the lung comparable to those induced by the
CD90+ cells. Anti-CD44 treatment decreased the number of lung nodules induced by the CD90+ cells. The bar chart demonstrates tumor formation rates of
different groups (n = 6 in each group). NT, no treatment. *p < 0.05, compared with the tumor formation rate induced by the CD90+CD44+ cells, NT; #p < 0.05,
compared with the CD90+ cells, NT.
(Cb) Flow cytometry using antibodies specifically targeting human CD44 and CD90 detected an enrichment of the CD90+CD44+ cells (9.16%) in lung lesions
induced by the CD90+ cells, compared to that of the primary tumor in the liver (2.53%).
(Cc) The photos display tumor nodules in the liver and lung of nude mice at 4 months after 10,000 CD90+ cell injection. White arrows point to the primary tumor
nodule in the liver and lung metastatic lesions, respectively. The histological features of the lung and primary tumor lesions are similar according to H&E staining.
IHC shows an increase in the number of CD90+ cells in the metastatic nodule. Black arrows indicate the CD90+ cells in the primary and secondary tumors,
respectively.
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Cancer Stem Cells in Liver MalignancyFigure 3. Tumorigenic Properties of the
CD45CD90+ Cells Isolated from Tumor
Tissues
(Aa) Flow cytometry was performed to identify the
CD45CD90+ and CD45CD90+CD44+ cells in
normal and cirrhotic liver, nontumorous, and tu-
mor tissue samples. As our preliminary data
showed that more than 90% of the CD90+ cells
were small in size, the CD45 cells were first gated
from the small cell region (R1), and the
CD90+CD44+ cells were then further analyzed in
the CD45 region (R2). A distinct population of
CD45CD90+CD44+ cells was detected in tumor
tissue (2.27%), but not in normal (0%), cirrhotic
(0%), or nontumorous liver samples (0.03%). The
dot plots represent one sample in each group.
(Ab) The distribution of CD90+ and CD44+ cells in
tumor tissue was confirmed by IF. Red, green,
and yellow arrows indicate the CD90+, CD44+,
and CD90+CD44+ cells, respectively.
(B) After dead cell removal, the CD45CD90+ cells
were isolated from tumor tissues with purity rang-
ing from 78.9% to 84.8% and injected into the left
lobe of the liver of SCID/Beige mice. The injected
CD45CD90+ cells, but not CD45CD90 cells,
generated tumor nodules in the liver of SCID/Beige
mice (a white arrow points to a tumor nodule) with
a similar histology to that of the primary tumor. IHC
of human hepatocyte recognized more than 90%
positive cells in the generated tumor nodule. A
black arrow indicates the cells expressing human
hepatocyte antigen. By IF, the CD90+CD44+ cells
were detected in the generated tumor tissues.
Red, green, and yellow arrows indicate the
CD90+, CD44+, and CD90+CD44+ cells, respec-
tively.Our preliminary data revealed that >80% viable cells were
required for the in vivo tumorigenicity assay. Among the 28 tumor
specimens collected, the cells isolated from 13 tumor specimens
showed >80% cell viability, and these cells were then used for
the in vivo tumorigenicity assay. After removal of dead cells,
the CD45CD90+ cells were isolated from individual tumor spec-
imens using magnetic microbeads and injected orthotopically
into the liver of individual severe-combined immunodeficient
(SCID)/Beige mice. The isolated CD45 cells (total tumor cell
control) from all the 13 tumor specimens formed tumor nodules
in immunodeficient mice with the cell number of 1 3 106 at
4 months after cell injection. At 3 months, the CD45CD90+ cells
from seven tumor specimens formed tumor nodules with the cell
number of 5,000, and after 4 months, the CD45CD90+ cells
from additional two tumor specimens developed tumor nodules
with the cell number of 5,000, and one mouse developed a tumor
nodule with 2,500 CD45CD90+ cells. An extension of the obser-
vation time to 5 months did not increase the number of tumor-
bearing mice. By comparison, when the cell number of the
CD45CD90+ cells was increased to 10,000, 100% of mice
developed tumors within 4 months (Table 3). In contrast, the
CD45CD90+ cells isolated from normal, cirrhotic, and nontumo-
rous liver tissues did not generate tumor nodules in SCID/Beige
mice. Likewise, the CD45CD90 cells from tumor tissues did
not develop tumor nodules, even after 5 months with 10,000
cells. Tumor xenografts displayed similar histological features
to primary tumors in liver cancer patients. IHC using antihuman
158 Cancer Cell 13, 153–166, February 2008 ª2008 Elsevier Inc.hepatocyte antibody, which specifically targets human antigens,
detected more than 90% positive cells in tumor xenografts. In
addition, IF detected CD90+CD44+ cells in the generated tumor
tissues (Figure 3B).
Based on the clinical observation that tumor recurrence rate is
high in HCC, even after curative hepatic resection or liver trans-
plantation, we postulate that CSCs might be present in the circu-
lation. To test this hypothesis, we investigated the number of
CD45CD90+ cells in blood samples by flow cytometry. A dis-
tinct population of CD45CD90+ cells was identified in 33 out
of 36 blood samples from liver cancer patients, but not in normal
and cirrhosis controls. Consistent with the findings in tumor
tissues, circulating CD45CD90+ cells also concomitantly ex-
pressed CD44 (Figure 4A and Table S3B).
In the next series of experiments, the CD45CD90+ cells were
isolated from blood samples from 10 HCC patients and injected
into the liver of SCID/Beige mice individually. At 4 months,
the CD45 cells (bulk control; cell number = 1 3 106) from all
the blood samples formed tumor nodules in immunodeficient
mice. At the same observation time, tumor formation was also in-
duced by 5,000 CD45CD90+ cells isolated from blood sample
of 5 HCC patients. When the cell number was increased to
10,000, circulating CD45CD90+ cells from all HCC patients
developed tumor nodules in the mice (Table 3). The generated
tumor nodules displayed similar histological features to the
primary tumors of liver cancer patients, and IHC revealed strong
expression of human hepatocyte antigen in tumor xenografts. IF
Cancer Cell
Cancer Stem Cells in Liver Malignancyshowed the presence of CD90+CD44+ cells in the tumor nodules
(Figure 4B).
Human CD90+ cells were then isolated from tumor xenografts
generated either by tumor tissue or circulating CD45CD90+
cells and injected into the liver of a second and, subsequently,
a third batch of SCID/Beige mice. In parallel experiments, the
CD90+ cells isolated from tumor xenografts displayed similar
tumorigenic properties to the CD45CD90+ cells isolated from
tumor specimens or blood samples after 3 or 4 months (Table
S2A). Flow cytometry detected a comparable number of human
CD90+ and CD90+CD44+ cells in the secondary and tertiary
tumor xenografts, though the proportion of CD90+CD44+ cells
within the pool of the CD90+ cells was higher in tumor xenografts
induced by circulating CD45CD90+ cells than in tumors in-
duced by tumor tissue CD45CD90+ cells (Table S2C).
Statistical analysis was performed to investigate the correla-
tion between the number of CD45CD90+ cells in tumor speci-
mens or blood samples and the clinicopathological parameters
of liver cancer patients. No significant correlation was identified
in the number of tumor tissue or circulating CD45CD90+ cells
and the gender, age (younger or older than 60 years), serum al-
pha-fetoprotein (AFP) level (lower or higher than 20 ng/ml), tumor
grading, and staging according to the American Joint Committee
on Cancer Tumor-Node-Metastasis. The number of circulating
CD45CD90+ cells was higher in patients with a tumor size larger
than 5 cm than in patients with a smaller tumor (1.47 ± 2.46% ver-
sus 0.15 ± 0.27%, p = 0.047) (Table S5). Due to the limited number
of cases and short follow-up period, the association between the
number of tumor tissue or circulating CD45CD90+ cells and dis-
ease-free survival or overall survival was not determined.
Differential Gene Expression Profiles Were Detected
in the CD45CD90+ Cells from Different Groups
Quantitative reverse transcriptase polymerase chain reaction
(qRT-PCR) was used to compare gene expression profiles of
the CD45CD90+ and CD45CD90 cells isolated from tissue
and blood samples of different groups. In tumor tissues, a signif-
icant upregulation ofCD44,Oct4,Bmi1, albumin, andAFPmRNA
was detected in the isolated CD45CD90+ cells, compared with
those sorted from normal, cirrhotic, and nontumorous liver
tissues (Figure 5A). The CD45CD90+ cells isolated from different
groups expressed a comparable level of Notch1 (Figure 5B).
In contrast, the expression of AFP, VIL2, MMP1, and JUNB
mRNA was significantly higher in the CD45CD90 cells sorted
from tumor tissues, compared with those isolated from control
tissues (Figure 5C). Finally, the expression of another group of
genes, includingWnt3a, signal transducers and activators of tran-
scription 3 (stat3), and hypoxia inducible factor-1a (HIF-1a), was
augmented in the CD45CD90+ cells isolated from cirrhotic, non-
tumorous and tumor tissues, prominently from cirrhotic and
nontumorous livers, compared with those from normal liver
tissues (Figure 5D).
In the circulation, the CD45CD90+ cells isolated from liver can-
cer patients expressed comparable levels ofOct4,Bmi1,Notch1,
Wnt3a, Stat3, and HIF-1a mRNA to tumor tissue CD45CD90+
cells, whereas circulating CD45CD90+ cells expressed a higher
level ofCD44 than those in tumor tissues. By comparison, a lower
level of albumin and AFP mRNA was detected in circulating
CD45CD90+ cells than those in tumor tissues (Figure 5).DISCUSSION
The present study reveals that CD90 is a potential marker for liver
CSCs. This is supported by the finding that the number of CD90+
cells isolated from all the HCC cell lines positively correlate with
tumorigenicity and metastatic potentials of cell lines, and the
CD45CD90+ cells isolated from tumor tissues and blood sam-
ples of liver cancer patients have the capacity to generate tumor
nodules in immunodeficient mice, whereas the CD90 or
CD45CD90 cells do not. The maintenance of tumorigenicity
of the CD90+ cells following propagation into a second and, sub-
sequently, a third batch of immunodeficient mice further sup-
ports CD90 as a marker for liver CSCs. Moreover, the CD90+
and CD45CD90+ cells reestablish the tumor cell hierarchy in
immunodeficient mice. Together, these data provide evidence
of the tumorigenicity and stem cell-like properties of the CD90+
or CD45CD90+ cells in human liver cancer.
Further characterization of the CD90+ cells was performed by
examining the expression of CD44, another stem cell marker, on
these cells. Consistent with the distribution of the CD45CD90+
cells in tumor specimens and blood, the CD45CD90+CD44+
cells were also detected locally and systemically in liver cancer
patients. Therefore, we hypothesize that the expression of addi-
tional stem cell markers on the CD90+ cells may represent differ-
ent subpopulations of CSCs. A similar multimarker hypothesis
has been suggested for CSCs in breast and pancreatic cancers
(Al-Hajj et al., 2003; Li et al., 2007). CD44 is an adhesion molecule
that regulates cell proliferation, migration, and invasion, by inter-
action with its ligands, heparanase, and hyaluronan, and, thus,
plays an important role in tumor progression and metastasis
(Go¨tte and Yip, 2006). Our preliminary results showed that the
sorted CD44+ cells from MHCC97L and PLC cell lines developed
tumor nodules in nude mice faster than the CD44 cells (Table
S6), supporting the role of CD44 in tumor progression. However,
the presence of CD45CD44+ cells in cirrhotic liver tissues (Fig-
ure 3A) hinders its application as a specific marker for liver CSCs
when used alone. The CD90+CD44+ phenotype of liver CSCs
might explain the aggressive growth pattern of HCC. In addition,
blockade of CD44 activity inhibited the survival of the CD90+
cells in vitro and prevented tumor engraftment in vivo, thereby
highlighting CD44 as a therapeutic target for the CD90+ CSCs.
Administration of anti-CD44 antibody had a more pronounced
effect on apoptosis of MHCC97L cells (inducing both CD90+
and CD90 cells undergoing apoptosis) than PLC cells (only in-
ducing CD90+ cells undergoing apoptosis). This finding supports
the observation that both CD90+ and CD90 cells in MHCC97L
cell line concomitantly express CD44, whereas only a small pro-
portion of the CD90 cells in PLC cell line concomitantly express
CD44. The effect of CD44 expression on the CD90 cells re-
mains to be explored. However, as the CD90 cells are not tu-
morigenic, while CD44 is only highly expressed by the CD90
cells in the cell lines with metastatic properties, we postulate
that CD44 expression on the CD90 cells might contribute to
the maintenance of metastatic properties of CSCs when they
are dividing into adult phenotypes. As cell viability is a major fac-
tor affecting tumor formation, especially after multiple-step sort-
ing procedures using magnetic microbeads, we did not specifi-
cally investigate the tumorigenicity of the CD45CD90+CD44+
and CD45CD90+CD44 cells from tumor tissues or blood
Cancer Cell 13, 153–166, February 2008 ª2008 Elsevier Inc. 159
Table 3. Tumorigenic Capacity of the CD45CD90+ Cells from Tumor Specimens and Blood Samples of Liver Cancer Patients
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of Mice with Cell Injection
(Range of Tumor Size [mm]) Patient
No.
Sample
Type
% of CD45CD90+
Cells
No. of Injected
Cells
Form
of Mi
(Rang
3 Months 4 Months 5 Months 3 Mo
1 tumor 2.56 2.5 3 103 0/2 0/2 0/2 1 blood 0.1 1 3 103 0/2
5 3 103 1/2 (3.5) 0/1 0/1 5 3 103 0/2
1 3 104 2/2 (6–7) 1 3 104 0/2
2 tumor 3.4 2.5 3 103 0/2 0/2 0/2 3 blood 1.42 1 3 103 0/2
5 3 103 0/2 0/2 0/2 5 3 103 0/2
1 3 104 1/2 (2) 0/1 0/1 1 3 104 0/2
3 tumor 3.89 2.5 3 103 0/2 0/2 0/2 4 blood 3.45 1 3 103 0/2
5 3 103 2/2 (1.8–4) 5 3 103 0/2
1 3 104 2/2 (6–8) 1 3 104 0/2
4 tumor 6.2 2.5 3 103 0/2 1/2 (2) 0/1 5 blood 0.49 1 3 103 0/2
5 3 103 2/2 (2.5–4) 5 3 103 0/2
1 3 104 2/2 (6.5–8) 1 3 104 0/2
5 tumor 1.51 2.5 3 103 0/2 0/2 0/2 7 blood 0.9 1 3 103 0/2
5 3 103 2/2 (5–8) 5 3 103 0/2
1 3 104 2/2 (7–8) 1 3 104 0/2
6 tumor 1.83 2.5 3 103 0/2 0/2 0/2 9 blood 0.08 1 3 103 0/2
5 3 103 1/2 (4) 0/1 0/1 5 3 103 0/2
1 3 104 1/2 (5.3) 0/1 0/1 1 3 104 0/2
7 tumor 2.34 2.5 3 103 0/2 0/2 0/2 11 blood 0.4 1 3 103 0/2
5 3 103 0/2 1/2 (1.5) 0/1 5 3 103 0/2
1 3 104 0/2 1/2 (2.5) 0/1 1 3 104 0/2
8 tumor 0.74 2.5 3 103 0/2 0/2 0/2 13 blood 0.13 1 3 103 0/2
5 3 103 0/2 1/2 (2) 0/1 5 3 103 0/2
1 3 104 0/2 1/2 (2.2) 0/1 1 3 104 0/2
9 tumor 4.14 2.5 3 103 0/2 0/2 0/2 14 blood 0.04 1 3 103 0/2
5 3 103 0/2 0/2 0/2 5 3 103 0/2
1 3 104 1/2 (3.8) 0/1 0/1 1 3 104 0/2
10 tumor 2.51 2.5 3 103 0/2 0/2 0/2 15 blood 0.07 1 3 103 0/2
5 3 103 1/2 (3.4) 0/1 0/1 5 3 103 0/2
1 3 104 1/2 (5) 0/1 0/1 1 3 104 0/2
11 tumor 2.24 2.5 3 103 0/2 0/2 0/2
5 3 103 0/2 0/2 0/2
1 3 104 1/2 (6.4) 0/1 0/1
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.samples. Instead, flow cytometry and IF were used to confirm
the presence of CD90+CD44+ cells in the generated tumor xeno-
grafts, and the data were consistent with the findings in HCC cell
lines.
Though both types of cells could generate tumors in immuno-
deficient mice, different genetic characteristics were identified
between tumor tissue and circulating CD45CD90+ cells. While
both highly expressed stem cell markers, Oct4, Bmi1, and
Wnt3a, tumor tissue CD45CD90+ cells expressed a higher level
of tissue specific markers, albumin and AFP. On the other hand,
circulating CD45CD90+ cells expressed a higher level of CD44
than the tumor tissue counterpart, suggesting that circulating
CSCs might harbor a more potent capacity to migrate and settle
in the target organs. The present study suggests that tumor tis-
sue CD45CD90+ cells are a source of the circulating counter-
part, as we have detected a decreased number of circulating
CD45CD90+ cells after hepatic resection (data not shown). In
addition, a higher number of circulating CD45CD90+ cells
were detected in the patients with a larger tumor size, suggesting
a positive correlation between the presence of circulating CSCs
and disease progression.
In our study, very low levels of CD45CD90+ cells are also pres-
ent in normal and cirrhotic liver tissues, and this finding is consis-
tent with others’ findings (Fiegel et al., 2003; Isabel et al., 2006;
Corcelle et al., 2006). Therefore, an investigation of the differ-
ences between the CD45CD90+ cells isolated from tumor spec-
imens or blood samples of liver cancer patients and those from
normal or cirrhotic liver tissues may provide important clues to un-
derstand the mechanism underlying hepatocarcinogenesis. By
qRT-PCR using specific primers, we have detected the augmen-
tation of Oct4 and Bmi1, which modulate stem cell self-renewal
and multipotency, in tumor tissue and circulating CD45CD90+
cells from liver cancer patients, thereby providing evidence of
the stem cell nature of these cells and their potential role in
hepatocarcinogenesis (Campbell et al., 2007; Bruggeman et al.,
2007). A comparable level of Notch1 expressed by both normal
hepatic and tumor tissue CD45CD90+ cells indicates their simi-
larity as stem cells (Chiba, 2006), signifying that this gene might
not play a prominent role in hepatocarcinogenesis. The enhanced
expression of CD44 in tumor specimens, and a greater enhance-
ment in circulating CD45CD90+ cells, confirmed our data
obtained from flow cytometry. The upregulation ofAFP and albu-
min in tumor tissue CD45CD90+ cells confirms these cells as
originating from the liver (Colli et al., 2006; Alison, 2006). The in-
creased expression of VIL2, MMP1, and JUNB in tumor tissue
CD45CD90 cells implies a role of these genes in the differenti-
ation of CSCs into adult phenotypes (Curto and McClatchey,
2004; Seiki, 2003; Jochum et al., 2001). Lastly, the expression
of another group of genes, Wnt3a, Stat3, and HIF-1a, was upre-
gulated in the CD45CD90+ cells isolated from cirrhotic livers,
nontumorous and tumor specimens, and blood samples of liver
cancer patients. This finding, and the observation that upregula-
tion was most prominent in cirrhotic and nontumorous livers,
implies a potential role of these genes in linking chronic injury to
hepatocarcinogenesis (Lee et al., 2006; Kim et al., 2007; Paul
et al., 2004; Yang et al., 2004a).
Using an antibody specifically targeting murine CD90, we de-
tected an increasing proportion of murine CD90+ cells in second-
ary and tertiary tumor xenografts (data not shown). This result
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Cancer Stem Cells in Liver MalignancyFigure 4. Tumorigenicity of the
CD45CD90+ Cells Isolated from Blood
Samples of Liver Cancer Patients
(A) More than 90% of the CD90+ cells isolated from
blood samples were identified in the small cell re-
gion. Using the same protocol to analyze the flow
cytometry data as that in tumor tissues, the
CD45CD90+CD44+ cells were detected in the
blood sample from liver cancer patients (0.12%),
but not in the normal (0%) and cirrhosis controls
(0%). The dot plots represent one sample in
each group, respectively.
(B) The CD45CD90+ and CD45CD90 cells
were isolated from blood samples of liver cancer
patients, with purity ranging from 81.9% to
84.5%, and injected into the left lobe of the liver
of SCID/Beige mice. The isolated CD45CD90+
cells, but not CD45CD90 cells, formed tumor
nodules in the liver of SCID/Beige mice. The white
arrow indicates a tumor nodule. H&E staining
of generated tumor nodules revealed a poorly
differentiated HCC. IHC detected more than
90% positive cells stained with the anti-human hepatocyte antibody. The black arrow indicates the cells expressing human hepatocyte antigen. IF recognized
both CD90+ and CD44+ cells in tumor xenograft. Red, green, and yellow arrows indicate the CD90+, CD44+, and CD90+CD44+ cells, respectively.suggests the formation of cell-cell fusions of human and murine
cells during the growth of human tumor in immunodeficient mice.
However, IHC studies using an antibody specifically targeting
human hepatocyte antigen demonstrated that more than 90%
of cells in tumor xenografts were human origin. Flow cytometry
using anti-human and anti-murine CD90 antibodies revealed
that <0.5% of the total cell population was double positive.
These results indicate that the proportion of cell-cell fusion in tu-
mor xenografts is low. We hypothesize that the murine CD90+
cells favor the survival, self-renewal, differentiation, and metas-
tasis of human CSCs mainly through participation in the estab-
lishment of a microenvironment (Gilbertson and Rich, 2007; Kar-
noub et al., 2007), rather than direct integration with human cells.
The present study has shown the presence of local and circu-
lating tumorigenic CD45CD90+, and an aggressive subpopula-
tion of CD90+CD44+ CSCs in human liver cancer. Due to the
small number of cases and short follow-up period, detailed sta-
tistical analyses could not be performed to evaluate the correla-
tion between the number of CSCs and clinico-pathological fea-
tures of liver cancer patients. The universal presence of the
CD45CD90+ cells in tumor tissues and more than 90% of blood
samples and a positive correlation between the number of circu-
lating CD45CD90+ cells and tumor size suggests that circulat-
ing CSCs could reflect tumor status and provide a cellular marker
for disease surveillance. In addition, the detectable levels of cir-
culating CD45CD90+ cells in patients with small tumors (<5 cm)
and dysplastic nodules reveal an important role of these
CD45CD90+ cells in early stage hepatocarcinogenesis. Finally,
the finding that inhibition of CD44 induces the death of CD90+
cells and prevents tumor engraftments both locally and system-
ically highlights the potential of targeting CD90+CD44+ CSCs for
tumor eradication in future therapeutic strategies.
EXPERIMENTAL PROCEDURES
Cell Lines
Human cell lines, MIHA (kindly provided by Dr. J. Roy-Chowdhury [Brown
et al., 2000]), HepG2, Hep3B, PLC, Huh7 (ATCC, Manassas, VA), MHCC97L,
162 Cancer Cell 13, 153–166, February 2008 ª2008 Elsevier Inc.and MHCC97H (HCC cell lines with low to high metastatic properties, respec-
tively [Tang et al., 2004]), were maintained as monolayer cultures in high glu-
cose Dulbecco’s Modified Eagle Medium (DMEM) with 10% fetal bovine
serum (FBS) and 1% penicillin (Life Technologies, Carlsbad, CA) at 37C in
a humidified atmosphere of 5% CO2 in air.
Patients and Sample Collection
Two patients with dysplastic nodules (2/2 were liver transplantation recipients)
and 36 patients with liver tumors who had undergone laparotomy (24/36 had
curative hepatic resection, 4/36 received liver transplantation, and 8/36 had
liver biopsy) were recruited in this study. Pathological diagnosis was made
according to the histology of tumor specimens or biopsy and examined by ex-
perienced pathologists. Nineteen patients with cirrhosis (10/19 received liver
transplantation) and 19 normal subjects (10/19 were liver donors) were used
as controls. The diagnosis of cirrhosis was made according to histological
findings in liver explants or CT/MRI scan results. The majority of patients
with HCC (28/36) and cirrhosis (15/19) were positive for serum hepatitis B
surface antigen (HBsAg). All tissue and blood samples were obtained from
consenting patients and approved by the Institutional Review Board of the
University of Hong Kong. The clinical data for the above patients and controls
are summarized in Table S3.
Tumor, parallel nontumorous, cirrhotic, and normal liver tissues were har-
vested at the time of operation and placed into DMEM medium. The procedure
of cell isolation from liver tissues was performed as previously described (Yang
et al., 2004b) with some modifications. In brief, after digestion with type IV
collagenase (100 units/ml) (Sigma-Aldrich, St. Louis, MO) at 37C for 15 min,
tissues were minced and cell suspension was passed through a 40 mM nylon
mesh. After lysis of red blood cells, cells were counted and subjected to flow
cytometry analysis or cell sorting.
Before the operation, 10 ml of EDTA blood were collected from patients and
controls. Mononuclear cells were isolated from the EDTA blood using Ficoll-
Paque PLUS (Amersham Bioscience, Buckinghamshire, England) density gra-
dient centrifugation before proceeding to flow cytometry analysis or cell
sorting.
Flow Cytometry
The isolated cells from HCC cell lines, tissue, and blood samples were labeled
with the following anti-human antibodies: FITC-ESA, FITC-CD44, PE-CD15,
PE-CD24, PE-CD30, PE-CD32, PE-CD33, PE-CD38, PE-CD56, PE-CD59,
PE-CK19, PE-CD117, PE-KDR, purified or PE-CD90, APC-CD45, APC-CD34
(BD Biosciences PharMingen, San Diego, CA), PE-Cy5-CD44, PE-Cy5-
CXCR4 (eBioscience, San Diego,CA), and PE-CD133 (Miltenyi Biotech Inc, Ber-
gisch Gladbach, Germany). Labeled cells were detected using a FACSCalibur
Cancer Cell
Cancer Stem Cells in Liver MalignancyFigure 5. Differential Gene Expression of the CD45CD90+ and CD45CD90 Cells Isolated from Tissue and Blood Samples of Different
Groups, Assessed by Using Quantitative Reverse Transcriptase Polymerase Chain Reaction
(Aa) The expression ofCD44,Oct4, andBmi1was specifically upregulated in the CD45CD90+ cells isolated from tumor tissues and blood samples of liver cancer
patients, compared with that in the CD45CD90+ cells isolated from normal livers. In addition, CD44 expression was even higher in the circulating CD45CD90+
cells than the tumor tissue counterpart.
(Ab) The expression of albumin and AFP was specifically upregulated in the CD45CD90+ cells isolated from tumor tissues, compared with that in the
CD45CD90+ cells sorted from normal liver tissues.
(B) The CD45CD90+ cells isolated from normal and cirrhotic livers, tumor tissues, and blood samples of liver cancer patients expressed a comparable level of
Notch1.
(C) The expression of VIL2, MMP1, and JUNB was exclusively upregulated in the CD45CD90 cells isolated from tumor tissues, compared with that in the
CD45CD90 cells sorted from normal liver tissues.
(D) The expression ofWnt3a,Stat3, andHIF-1awas augmented in the CD45CD90+ cells isolated from cirrhotic livers, nontumorous and tumor tissues, and blood
samples from liver cancer patients. The data present at least five samples in each group. Nor, normal liver; Cir, cirrhotic liver; NT, nontumorous; T, tumor; T-blood,
blood samples from liver cancer patients.(Becton Dickinson Immunocytometry Systems, San Jose, CA). Appropriate
isotypes of nonrelated antibodies were used as controls. A dead cell removal
procedurewas performed before antibody labelingand flow cytometryanalysis.
Cell Sorting
Cocktail PE-conjugated mouse anti-human CD90 and FITC-conjugated anti-
human CD44 antibody were made according to the manufacturer’s instructions
(StemCell Technologies Inc., Miami, Florida). The cells from MHCC97L or PLC
cell lines were suspended in PBS with 2% FBS and 0.5 mM EDTA, sequentially
labeled with anti-CD90 and anti-CD44 antibody cocktail, and mixed with mag-
netic microbeads. The CD90+ and CD90 cells, and subsequent CD90+CD44+
and CD90+CD44 cells, were then separated using a magnet. The purity of
sorted cells was evaluated by flow cytometry. For the isolation of cells fromtumor specimens and blood samples, a modified protocol was performed,
including dead cell removal and subsequent two-step separation procedure
involving CD45 depletion and CD90 selection (Miltenyi Biotech Inc). The tumor-
igenicity of CD45CD90+ cells isolated from tumor tissues or blood was char-
acterized by injecting the sorted cells into immunodeficient mice. The viability of
sorted cells was assessed by trypan blue staining, and >80% cell viability was
set as the requirement for the in vivo tumorigenicity assay.
Tumor Xenografts in BALB/c Nude Mice or SCID/Beige Mice
Male BALB/c nude mice and SCID/Beige mice, aged 4 to 5 weeks, were pur-
chased from the Animal Laboratory Unit of the University of Hong Kong. The
mice were maintained under standard conditions and cared for according
to the institutional guidelines for animal care. All the animal experiments were
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search of the University of Hong Kong. The tumor cells from HCC cell lines
have the capacity to generate tumor nodules on the back of BALB/c nude
mice (Tian et al., 1999). Hence, the CD90+ and CD90 cells isolated from differ-
ent HCC cell lines were injected subcutaneously into two sides of the same
nude mouse, respectively, for controlled visualization and comparison. To fa-
vor cell growth, the cells isolated from human tumor tissues and blood samples
were injected orthotopically into the left lobe of the liver of SCID/Beige mice as
previously described (Yang et al., 2005). To generate a metastatic tumor model,
the sorted CD90+, CD90, CD90+CD44+, and CD90+CD44 cells isolated from
MHCC97L cell line were injected orthotopically into the liver of different BALB/c
nude mice. A total of 1 3 106 tumor cells were injected into immunodeficient
mice to serve as a control of cell viability. Animals were sacrificed at the indi-
cated time intervals when tumor nodules were identified on the body surface
of nude mice or in the liver of SCID/Beige mice by laparotomy. If tumors were
not identified, the abdominal incision was closed by sutures, and the mice
were monitored until the second or third time point. In the tumor metastasis
model, animals were sacrificed at 4 months after cell injection to investigate
the formation of liver and lung lesions.
Blockade of CD44 Activity In Vitro and In Vivo
For in vitro experiments, the CD90+ and CD90 cells isolated from HCC cell
lines were treated for 24 hr with different doses (0, 1.5, 3, 6, 12, or 24 mg/ml)
of anti-human CD44 antibody (International Blood Group Reference Labora-
tory, Bristol, England). The cells were then labeled with Annexin-V and Propi-
dium iodide (PI) (BD Biosciences PharMingen) and detected in a FACSCalibur
(Becton Dickinson Immunocytometry Systems).
For in vivo experiments, 5,000 or 10,000 CD90+ cells were isolated from
HCC cell line and injected subcutaneously into BALB/c nude mice. In the
lung metastasis model, the CD90+ and CD90 cells were isolated from
MHCC97L cell line and injected into the left lobe of the liver of BALB/c nude
mice, respectively. At the time of cell inoculation, anti-human CD44 antibody
was administered intravenously (5 mg/kg or 10 mg/kg twice per week). The
mice were monitored continuously for signs of subcutaneous tumor forma-
tion, or sacrificed at 4 months to investigate tumor formation in the liver and
lung.
Histological Studies
The embedded tissues were cut into 5 mm-thick sections for histological anal-
yses by H&E staining, IHC to detect CD90 and human hepatocytes (Dako,
Glostrup, Denmark), and IF to examine CD44 and CD90 expression. The
anti-human hepatocyte antibody recognizes human liver tumors by IHC (Min-
ervini et al., 1997). Our preliminary investigations showed that the anti-human
hepatocyte antibody did not crossreact with murine antigen. Sections were in-
cubated sequentially with primary and secondary antibodies for 1 hr at room
temperature. Counter-staining of the nucleus was performed using hematox-
ylin and DAPI for IHC and IF, respectively.
Real-Time Quantitative Reverse Transcriptase
Polymerase Chain Reaction
Total RNA was extracted from the isolated CD45CD90+ and CD45CD90
cells from tissue or blood using the RNeasy RNA Mini Kit (QIAGEN Inc., Valen-
cia, CA). RNA was resuspended in 30 ml RNase-free water. First strand cDNA
was synthesized by using ImProm-II reverse transcriptase (Promega, Madi-
son, WI). Real-time qPCR was performed using the first strand cDNA, 10 mM
forward and reverse primers, and the SYBR Green PCR master mix. The
primer sequences and PCR conditions are summarized in Table S7. The reac-
tions were performed using the ABI PRISM 7700 Sequence Detector (Applied
Biosystems, Foster City, CA). Fluorescence signals were analyzed using SDS
1.9.1 software (Applied Biosystems). Expression levels were calculated as the
relative expression ratio compared to b-actin. Since the CD45CD90+ cells
could only be isolated from tissue, but not blood, samples of normal and cir-
rhosis controls, a comparison of gene expression profiles was performed be-
tween the CD45CD90+ or CD45CD90 cells isolated from tumor and control
tissues and between the CD45CD90+ or CD45CD90 cells isolated from
blood samples of liver cancer patients and those isolated from tumor speci-
mens. As the number of isolated cells was usually small, following confirmation
164 Cancer Cell 13, 153–166, February 2008 ª2008 Elsevier Inc.of cell purity, at least five samples from each source were pooled together to
obtain reliable gene expression data.
Statistical Analysis
Comparison of apoptotic cell number and tumor formation rate with different
treatments, and the number of tumor tissue and circulating CD45CD90+ cells
in different tumor size groups, were performed using Student’s t test. SPSS
software (version 12.0 for Windows; SPSS Inc., Chicago, IL) was used for all
statistical analyses. A p value less than 0.05 was considered statistically
significant.
Supplemental Data
The Supplemental Data include seven supplemental tables and can be found
with this article online at http://www.cancercell.org/cgi/content/full/13/2/153/
DC1/.
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